Related Experiment Video

Updated: Apr 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer

Marinus R Heideman1, Anna Frei2, Nancy E Hynes3

  • 1Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

Cancer Discovery
|September 4, 2015
PubMed

Insights

Tamoxifen resistance in breast cancer is a major problem. Researchers discovered a new ER/HOXB7 signaling loop that could be targeted to treat tamoxifen-resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Estrogen receptor-positive (ER(+)) breast cancer is common.
  • Tamoxifen is a standard endocrine therapy for ER(+) breast cancer.
  • Tamoxifen resistance and tumor recurrence are significant clinical challenges.

Purpose of the Study:

  • To identify novel mechanisms driving tamoxifen resistance in breast cancer.
  • To investigate the role of the ER/HOXB7 signaling pathway in tamoxifen resistance.

Main Methods:

  • Utilized tamoxifen-resistant breast cancer models.
  • Investigated the interplay between estrogen receptor (ER) and HOXB7 signaling.
  • Assessed the therapeutic potential of targeting the ER/HOXB7 loop.

Main Results:

  • Identified a novel signaling loop involving ER and HOXB7 in tamoxifen-resistant breast cancer.
  • Demonstrated that this ER/HOXB7 loop contributes to tamoxifen resistance.

Conclusions:

  • The ER/HOXB7 signaling loop represents a potential therapeutic target.
  • Targeting this pathway may overcome tamoxifen resistance in breast cancer patients.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K